2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T96f,Tranexamic acid (TXA) is increasingly used to minimize perioperative bleeding. However, its efficacy and safety profile across general surgical procedures remains unclear. To evaluate the efficacy and safety of prophylactic TXA in reducing intraoperative blood loss, need for transfusion, and major bleeding in general surgery, while assessing its association with thromboembolic events and mortality. PubMed, Embase, and Cochrane Library were systematically searched from inception to April 3, 2025. Randomized clinical trials (RCTs) comparing TXA to placebo in adult patients undergoing general surgery and reporting at least 1 predefined outcome of interest were included. Two reviewers independently extracted data and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% CIs were pooled using random-effects models. Heterogeneity was assessed using the I2 statistic. Twenty-six RCTs with a total of 6976 patients were included. TXA use was associated with lower intraoperative blood loss (MD, -35.85 mL; 95% CI, -57.20 to -14.51 mL; I2 = 91%; P = .001), reduced need for transfusion (RR, 0.75; 95% CI, 0.60-0.94; I2 = 54%; P = .01), and fewer major bleeding events (RR, 0.72; 95% CI, 0.59-0.89; I2 = 0%; P = .002). No significant differences were found in venous thromboembolism (RR, 1.09; 95% CI, 0.62-1.92; I2 = 15%; P = .75), mortality (RR, 1.08; 95% CI, 0.72-1.61; I2 = 0%; P = .71), and length of stay (MD, -0.54 days; 95% CI, -1.15 to 0.06 days; I2 = 73%; P = .08). In the subgroup analysis restricted to abdominal procedures, the benefits observed in the overall population on intraoperative blood loss and need for transfusion were no longer present. In the hepatobiliary subgroup, TXA was associated with a significant reduction in major bleeding (RR, 0.59; 95% CI, 0.39-0.90; I2 = 0%; P = .01), while no significant differences were observed for the other outcomes. This systematic review and meta-analysis found that prophylactic TXA use was associated with lower intraoperative blood loss, transfusion requirements, and major bleeding without an observed increase in thromboembolic or mortality risk. Although these findings support the use of TXA in general surgery procedures, the decision to use TXA should be individualized considering individual patient characteristics and the specific procedure being performed.31:T14f3, Importance Tranexamic acid (TXA) is increasingly used to minimize perioperative bleeding. However, its efficacy and safety profile across general surgical procedures remains unclear. Objective To evaluate the efficacy and safety of prophylactic TXA in reducing intraoperative blood loss, need for transfusion, and major bleeding in general surgery, while assessing its association with thromboembolic events and mortality. Data Sources PubMed, Embase, and Cochrane Library were systematically searched from inception to April 3, 2025. Study Selection Randomized clinical trials (RCTs) comparing TXA to placebo in adult patients undergoing general surgery and reporting at least 1 predefined outcome of interest were included. Data Extraction and Synthesis Two reviewers independently extracted data and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% CIs were pooled using random-effects models. Heterogeneity was assessed using the I 2 statistic. Results Twenty-six RCTs with a total of 6976 patients were included. TXA use was associated with lower intraoperative blood loss (MD, −35.85 mL; 95% CI, −57.20 to −14.51 mL; I 2 = 91%; P = .001), reduced need for transfusion (RR, 0.75; 95% CI, 0.60-0.94; I 2 = 54%; P = .01), and fewer major bleeding events (RR, 0.72; 95% CI, 0.59-0.89; I 2 = 0%; P = .002). No significant differences were found in venous thromboembolism (RR, 1.09; 95% CI, 0.62-1.92; I 2 = 15%; P = .75), mortality (RR, 1.08; 95% CI, 0.72-1.61; I 2 = 0%; P = .71), and length of stay (MD, −0.54 days; 95% CI, −1.15 to 0.06 days; I 2 = 73%; P = .08). In the subgroup analysis restricted to abdominal procedures, the benefits observed in the overall population on intraoperative blood loss and need for transfusion were no longer present. In the hepatobiliary subgroup, TXA was associated with a significant reduction in major bleeding (RR, 0.59; 95% CI, 0.39-0.90; I 2 = 0%; P = .01), while no significant differences were observed for the other outcomes. Conclusions and Relevance This systematic review and meta-analysis found that prophylactic TXA use was associated with lower intraoperative blood loss, transfusion requirements, and major bleeding without an observed increase in thromboembolic or mortality risk. Although these findings support the use of TXA in general surgery procedures, the decision to use TXA should be individualized considering individual patient characteristics and the specific procedure being performed. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Perioperative Bleeding: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Perioperative Bleeding (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Perioperative%20Bleeding\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Perioperative Bleeding\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Perioperative%20Bleeding\"}]}}"}}]],["$","$L2f",null,{"title":"Perioperative Bleeding: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Perioperative Bleeding with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1016/j.eururo.2026.03.019","pmid":"42020258","title":"Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial","journal_title":"European Urology","journal_issn":"0302-2838","published_at":"2026-04-21T00:00:00.000Z","url":"https://doi.org/10.1016/j.eururo.2026.03.019","source_score":29,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:49:51.658Z","updated_at":"2026-05-07T22:49:51.658Z","tags":[{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"condition","value":"Perioperative Bleeding","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"condition","value":"Urologic Surgery","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"generic","value":"tranexamic acid","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"modality","value":"Antifibrinolytic Agent","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"sample_size","value":"n=1124","value_numeric":1124},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously given the subgroup-analysis design, but the finding fills a clear gap in urologic guidelines.","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"warning","value":"The primary composite bleeding endpoint did not reach statistical significance (HR 0.73, CI crosses 1.0); the significant result applies specifically to the major bleeding subcomponent.","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.03.019","tag_type":"warning","value":"This is a pre-specified subgroup analysis of the broader POISE-3 trial, not a standalone RCT — findings should be interpreted with that context in mind.","value_numeric":null}],"summaries":{"what_studied":"This pre-specified subgroup analysis of the POISE-3 international RCT evaluated TXA (1 g IV at surgery start and end) vs. placebo in 1,124 patients undergoing urologic surgery (laparoscopic/robotic, open, transurethral, or percutaneous) over a 30-day follow-up period.","key_result":"TXA reduced major bleeding (6.1% vs. 9.5%; HR 0.63, 95% CI 0.41–0.97) and showed a non-significant trend toward reduced composite bleeding (8.1% vs. 10.9%; HR 0.73, 95% CI 0.50–1.07). The composite thrombotic safety outcome was similar between arms (12.1% vs. 10.9%; HR 1.12, 95% CI 0.79–1.58), with no meaningful difference in MINS, stroke, or VTE.","limitations":"- This is a subgroup analysis; the composite bleeding reduction did not reach statistical significance.\n- Patient-important thrombotic events (stroke, VTE) were rare, limiting precision for those estimates.\n- No subgroup interactions were found by surgical approach, cancer status, or antithrombotic use, but individual subgroups may have been underpowered.","practice_takeaway":"TXA (1 g IV at start and end of surgery) significantly reduced major bleeding in urologic surgery without a clear increase in thrombotic risk — consider its use, particularly in higher-risk bleeding cases. Major urologic guidelines currently lack recommendations on TXA; this data supports updating that guidance."}},{"doi":"10.1001/jamasurg.2025.5498","pmid":"41405985","title":"Perioperative Use of Tranexamic Acid in General Surgery","journal_title":"JAMA Surgery","journal_issn":"2168-6254","published_at":"2025-12-17T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12712826/","source_score":138,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-19","doi":"10.1001/jamasurg.2025.5498","days":"30","issn":"2168-6254","rank":"4","field":"Clinical Medicine","score":"138","category":"Surgery","categories":["Surgery"],"_categories":["Surgery"]},"pubmed":{"doi":"10.1001/jamasurg.2025.5498","title":"Perioperative Use of Tranexamic Acid in General Surgery: A Systematic Review and Meta-Analysis.","journal":"JAMA surgery","methods":"","results":"Twenty-six RCTs with a total of 6976 patients were included. TXA use was associated with lower intraoperative blood loss (MD, -35.85 mL; 95% CI, -57.20 to -14.51 mL; I2 = 91%; P = .001), reduced need for transfusion (RR, 0.75; 95% CI, 0.60-0.94; I2 = 54%; P = .01), and fewer major bleeding events (RR, 0.72; 95% CI, 0.59-0.89; I2 = 0%; P = .002). No significant differences were found in venous thromboembolism (RR, 1.09; 95% CI, 0.62-1.92; I2 = 15%; P = .75), mortality (RR, 1.08; 95% CI, 0.72-1.61; I2 = 0%; P = .71), and length of stay (MD, -0.54 days; 95% CI, -1.15 to 0.06 days; I2 = 73%; P = .08). In the subgroup analysis restricted to abdominal procedures, the benefits observed in the overall population on intraoperative blood loss and need for transfusion were no longer present. In the hepatobiliary subgroup, TXA was associated with a significant reduction in major bleeding (RR, 0.59; 95% CI, 0.39-0.90; I2 = 0%; P = .01), while no significant differences were observed for the other outcomes.","abstract":"$30","keywords":[],"pubmed_id":"41405985","conclusions":"","publication_date":"2025-12-17T00:00:00"},"crossref":{"DOI":"10.1001/jamasurg.2025.5498","URL":"https://doi.org/10.1001/jamasurg.2025.5498","ISSN":["2168-6254"],"link":[{"URL":"https://jamanetwork.com/journals/jamasurgery/articlepdf/2843043/jamasurgery_delgado_2025_oi_250084_1765563894.45277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Perioperative Use of Tranexamic Acid in General Surgery"],"author":[{"given":"Lucas Monteiro","family":"Delgado","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil"}]},{"given":"Bernardo Fontel","family":"Pompeu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Heliópolis Hospital, São Paulo-SP, Brazil"},{"name":"Universidade Municipal de São Caetano do Sul (USCS), São Paulo-SP, Brazil"}]},{"given":"Gabriel Henrique Acedo","family":"Martins","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil"}]},{"given":"Mariana Lima","family":"Azevedo","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil"}]},{"given":"Eric","family":"Pasqualotto","sequence":"additional","affiliation":[{"name":"Universidade Federal de Santa Catarina, Florianópolis-SC, Brazil"}]},{"given":"Thiago Celestino","family":"Chulam","sequence":"additional","affiliation":[{"name":"AC Camargo Cancer Center, São Paulo-SP, Brazil"},{"name":"Universidade Federal do Espírito Santo, Vitória-ES, Brazil"}]},{"given":"Sérgio Mazzola Poli","family":"de Figueiredo","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of North Carolina, Chapel Hill, North Carolina"}]}],"issued":{"date-parts":[[2025,12,17]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-12-17T17:30:28Z","timestamp":1765992628000,"date-parts":[[2025,12,17]]},"indexed":{"date-time":"2025-12-17T17:32:28Z","timestamp":1765992748256,"date-parts":[[2025,12,17]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamasurgery/fullarticle/2843043"}},"subtitle":["A Systematic Review and Meta-Analysis"],"deposited":{"date-time":"2025-12-17T17:30:29Z","timestamp":1765992629000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"2168-6254"}],"published":{"date-parts":[[2025,12,17]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1136/jcp.s3-14.1.41","key":"soi250084r1","year":"1980","issue":null,"author":"Nilsson","volume":"14","first-page":"41","unstructured":null,"article-title":"Clinical pharmacology of aminocaproic and tranexamic acids.","journal-title":"J Clin Pathol Suppl (R Coll Pathol)","doi-asserted-by":"publisher"},{"DOI":"10.2165/11209070-000000000-00000","key":"soi250084r2","year":"2012","issue":"5","author":"McCormack","volume":"72","first-page":"585","unstructured":null,"article-title":"Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.","journal-title":"Drugs","doi-asserted-by":"publisher"},{"DOI":"10.1097/XCS.0000000000001163","key":"soi250084r3","year":"2024","issue":"5","author":"Park","volume":"239","first-page":"S171","unstructured":null,"article-title":"Safety and efficacy of tranexamic acid use in general surgery patients: a sub-study of the POISE-3 randomized controlled trial.","journal-title":"J Am Coll Surg","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1606424","key":"soi250084r4","year":"2017","issue":"2","author":"Myles","volume":"376","first-page":"136","unstructured":null,"article-title":"Tranexamic acid in patients undergoing coronary-artery surgery.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtcvs.2018.09.113","key":"soi250084r5","year":"2019","issue":"2","author":"Myles","volume":"157","first-page":"644","unstructured":null,"article-title":"Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.","journal-title":"J Thorac Cardiovasc Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.arthro.2021.10.001","key":"soi250084r6","year":"2022","issue":"4","author":"Goldstein","volume":"38","first-page":"1366","unstructured":null,"article-title":"Tranexamic acid administration in arthroscopic surgery is a safe adjunct to decrease postoperative pain and swelling: a systematic review and meta-analysis.","journal-title":"Arthroscopy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.arthro.2021.07.030","key":"soi250084r7","year":"2022","issue":"2","author":"Alkhatib","volume":"38","first-page":"506","unstructured":null,"article-title":"Tranexamic acid use in anterior cruciate ligament reconstruction decreases bleeding complications: a systematic review and meta-analysis of randomized controlled trials.","journal-title":"Arthroscopy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bjps.2024.09.085","key":"soi250084r8","year":"2025","issue":null,"author":"Rohrich","volume":"102","first-page":"373","unstructured":null,"article-title":"Role of tranexamic acid (TXA) in plastic and reconstructive surgery: a national perspective.","journal-title":"J Plast Reconstr Aesthet Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ahj.2023.02.008","key":"soi250084r10","year":"2023","issue":null,"author":"Smilowitz","volume":"260","first-page":"26","unstructured":null,"article-title":"Perioperative bleeding and outcomes after noncardiac surgery.","journal-title":"Am Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.n71","key":"soi250084r12","year":"2021","issue":"71","author":"Page","volume":"372","first-page":"n71","unstructured":null,"article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.l4898","key":"soi250084r15","year":"2019","issue":null,"author":"Sterne","volume":"366","first-page":"l4898","unstructured":null,"article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.328.7454.1490","key":"soi250084r16","year":"2004","issue":"7454","author":"Atkins","volume":"328","first-page":"1490","unstructured":null,"article-title":"Grading quality of evidence and strength of recommendations.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.315.7109.629","key":"soi250084r17","year":"1997","issue":"7109","author":"Egger","volume":"315","first-page":"629","unstructured":null,"article-title":"Bias in meta-analysis detected by a simple, graphical test.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/0197-2456(86)90046-2","key":"soi250084r18","year":"1986","issue":"3","author":"DerSimonian","volume":"7","first-page":"177","unstructured":null,"article-title":"Meta-analysis in clinical trials.","journal-title":"Control Clin Trials","doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.1221","key":"soi250084r19","year":"2002","issue":"18","author":"Baujat","volume":"21","first-page":"2641","unstructured":null,"article-title":"A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials.","journal-title":"Stat Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.11","key":"soi250084r20","year":"2010","issue":"2","author":"Viechtbauer","volume":"1","first-page":"112","unstructured":null,"article-title":"Outlier and influence diagnostics for meta-analysis.","journal-title":"Res Synth Methods","doi-asserted-by":"publisher"},{"DOI":"10.1111/anae.14705","key":"soi250084r21","year":"2020","issue":"1","author":"Shah","volume":"75","first-page":"15","unstructured":null,"article-title":"Trial sequential analysis: adding a new dimension to meta-analysis.","journal-title":"Anaesthesia","doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.1187","key":"soi250084r22","year":"2002","issue":"11","author":"Thompson","volume":"21","first-page":"1559","unstructured":null,"article-title":"How should meta-regression analyses be undertaken and interpreted?","journal-title":"Stat Med","doi-asserted-by":"publisher"},{"DOI":"10.5005/jp-journals-10033-1266","key":"soi250084r23","year":"2016","issue":"1","author":"Alhomoud","volume":"9","first-page":"30","unstructured":null,"article-title":"The effect of tranexamic acid on blood loss during laparoscopic sleeve gastrectomy.","journal-title":"World J Laparosc Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/00000542-199611000-00012","key":"soi250084r24","year":"1996","issue":"5","author":"Boylan","volume":"85","first-page":"1043","unstructured":null,"article-title":"Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation.","journal-title":"Anesthesiology","doi-asserted-by":"publisher"},{"DOI":"10.1097/00000539-200007000-00006","key":"soi250084r25","year":"2000","issue":"1","author":"Dalmau","volume":"91","first-page":"29","unstructured":null,"article-title":"Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation.","journal-title":"Anesth Analg","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2024.11783","key":"soi250084r26","year":"2024","issue":"13","author":"Karanicolas","volume":"332","first-page":"1080","unstructured":null,"article-title":"Tranexamic acid in patients undergoing liver resection: the HeLiX randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12871-025-02935-0","key":"soi250084r27","year":"2025","issue":"1","author":"Luo","volume":"25","first-page":"94","unstructured":null,"article-title":"Use of tranexamic acid in hepatectomy under controlled low central venous pressure: a randomized controlled study.","journal-title":"BMC Anesthesiol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11695-023-06902-x","key":"soi250084r29","year":"2023","issue":"12","author":"Sermet","volume":"33","first-page":"3962","unstructured":null,"article-title":"Effect of tranexamic acid on postoperative bleeding in sleeve gastrectomy: a randomized trial.","journal-title":"Obes Surg","doi-asserted-by":"publisher"},{"DOI":"10.53350/pjmhs20221611531","key":"soi250084r30","year":"2022","issue":"11","author":"Siddiqui","volume":"16","first-page":"531","unstructured":null,"article-title":"Peri-operative use of transexamic acid in reduction of post operative seroma formation in patients undergoing ventral hernia repair.","journal-title":"Pak J Med Health Sci","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00464-023-10232-5","key":"soi250084r31","year":"2023","issue":"10","author":"’t Hart","volume":"37","first-page":"7455","unstructured":null,"article-title":"Peroperative administration of tranexamic acid in sleeve gastrectomy to reduce hemorrhage: a double-blind randomized controlled trial.","journal-title":"Surg Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjs/znac382","key":"soi250084r32","year":"2023","issue":"2","author":"Ishii","volume":"110","first-page":"159","unstructured":null,"article-title":"Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.","journal-title":"Br J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/01.sla.0000197561.70972.73","key":"soi250084r33","year":"2006","issue":"2","author":"Wu","volume":"243","first-page":"173","unstructured":null,"article-title":"Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a “blood transfusion”-free hepatectomy.","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.2147/JPR.S426872","key":"soi250084r34","year":"2023","issue":null,"author":"Yang","volume":"16","first-page":"3905","unstructured":null,"article-title":"Safe and Effective Blood Preservation Through Acute Normovolemic Hemodilution and Low-Dose Tranexamic Acid in Open Partial Hepatectomy.","journal-title":"J Pain Res","doi-asserted-by":"publisher"},{"DOI":null,"key":"soi250084r35","year":"2021","issue":null,"author":"Zaheer","volume":null,"first-page":null,"unstructured":null,"article-title":"Single dose of IV tranexamic acid preoperatively reduces the incidence of post-operative scrotal edema following lichtenstein hernioplasty. a randomized prospective cohort analysis.","journal-title":"Medical Forum Monthly","doi-asserted-by":null},{"DOI":"10.1016/j.jclinane.2011.03.004","key":"soi250084r36","year":"2011","issue":"8","author":"Alimian","volume":"23","first-page":"611","unstructured":null,"article-title":"The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial.","journal-title":"J Clin Anesth","doi-asserted-by":"publisher"},{"DOI":"10.1007/BF01773442","key":"soi250084r37","year":"1987","issue":"6","author":"Auvinen","volume":"65","first-page":"253","unstructured":null,"article-title":"Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland.","journal-title":"Klin Wochenschr","doi-asserted-by":"publisher"},{"DOI":"10.7759/cureus.20190","key":"soi250084r38","year":"2021","issue":"12","author":"Babu","volume":"13","first-page":null,"unstructured":null,"article-title":"Effect of two different tranexamic acid doses on blood loss in head and neck cancer surgery: a randomized, double-blind, controlled study.","journal-title":"Cureus","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.otohns.2008.02.022","key":"soi250084r39","year":"2008","issue":"6","author":"Chen","volume":"138","first-page":"762","unstructured":null,"article-title":"Prospective, randomized, controlled trial of tranexamic acid in patients who undergo head and neck procedures.","journal-title":"Otolaryngol Head Neck Surg","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12070-010-0095-4","key":"soi250084r40","year":"2011","issue":"1","author":"George","volume":"63","first-page":"20","unstructured":null,"article-title":"A randomized control trial to verify the efficacy of pre-operative intra venous tranexamic acid in the control of tonsillectomy bleeding.","journal-title":"Indian J Otolaryngol Head Neck Surg","doi-asserted-by":"publisher"},{"DOI":"10.4103/0019-5049.174798","key":"soi250084r41","year":"2016","issue":"1","author":"Kulkarni","volume":"60","first-page":"19","unstructured":null,"article-title":"Does tranexamic acid reduce blood loss during head and neck cancer surgery?","journal-title":"Indian J Anaesth","doi-asserted-by":"publisher"},{"DOI":"10.7860/JCDR/2019/42939.13349","key":"soi250084r42","year":"2019","issue":"12","author":"Pannerselvam","volume":"13","first-page":"UC05","unstructured":null,"article-title":"Comparative study of two different intravenous doses of tranexamic acid with placebo on surgical field quality in functional endoscopic sinus surgery—a randomised clinical trial.","journal-title":"J Clin Diagn Res","doi-asserted-by":"publisher"},{"DOI":"10.1017/S0022215119002305","key":"soi250084r43","year":"2019","issue":"12","author":"Thakur","volume":"133","first-page":"1024","unstructured":null,"article-title":"Tranexamic acid has no advantage in head and neck surgical procedures: a randomised, double-blind, controlled clinical trial.","journal-title":"J Laryngol Otol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fsurg.2021.771159","key":"soi250084r44","year":"2021","issue":null,"author":"Yang","volume":"8","first-page":null,"unstructured":null,"article-title":"Intravenous tranexamic acid improves the intraoperative visualization of endoscopic sinus surgery for high-grade chronic rhinosinusitis: a randomized, controlled, double-blinded prospective trial.","journal-title":"Front Surg","doi-asserted-by":"publisher"},{"DOI":"10.4103/ija.ija_576_22","key":"soi250084r45","year":"2023","issue":"2","author":"Shaker","volume":"67","first-page":"194","unstructured":null,"article-title":"Evaluation of efficacy and safety of a single dose tranexamic acid in reducing blood loss during colorectal cancer surgery: a randomised, placebo controlled, double-blinded study.","journal-title":"Indian J Anaesth","doi-asserted-by":"publisher"},{"DOI":null,"key":"soi250084r46","year":"2020","issue":"3","author":"Ziaei","volume":"10","first-page":"46","unstructured":null,"article-title":"Does intravenous tranexamic acid reduce bleeding during mastoidectomy?","journal-title":"Am J Blood Res","doi-asserted-by":null},{"DOI":"10.1097/00000539-199708000-00007","key":"soi250084r47","year":"1997","issue":"2","author":"Kaspar","volume":"85","first-page":"281","unstructured":null,"article-title":"Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation.","journal-title":"Anesth Analg","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(10)60835-5","key":"soi250084r48","year":"2010","issue":"9734","author":"Shakur","volume":"376","first-page":"23","unstructured":null,"article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1097/CCM.0000000000005362","key":"soi250084r49","year":"2022","issue":"3","author":"Dionne","volume":"50","first-page":"e313","unstructured":null,"article-title":"Tranexamic acid in gastrointestinal bleeding: a systematic review and meta-analysis.","journal-title":"Crit Care Med","doi-asserted-by":"publisher"},{"DOI":"10.1097/HEP.0000000000000817","key":"soi250084r50","year":"2024","issue":"2","author":"Kumar","volume":"80","first-page":"376","unstructured":null,"article-title":"Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: a randomized controlled trial.","journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.hpb.2025.05.006","key":"soi250084r51","year":"2025","issue":"8","author":"de Jesus","volume":"27","first-page":"1009","unstructured":null,"article-title":"Safety and efficacy of tranexamic acid in hepatic surgery: a meta-analysis of randomized controlled trials.","journal-title":"HPB (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1177/10760296251342467","key":"soi250084r52","year":"2025","issue":null,"author":"Tanashat","volume":"31","first-page":null,"unstructured":null,"article-title":"Tranexamic acid in patients undergoing liver resection: an updated systematic review and meta-analysis of randomized controlled trials.","journal-title":"Clin Appl Thromb Hemost","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2019.03.070","key":"soi250084r53","year":"2019","issue":"1","author":"O’Leary","volume":"157","first-page":"34","unstructured":null,"article-title":"AGA clinical practice update: coagulation in cirrhosis.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.athoracsur.2024.06.039","key":"soi250084r54","year":"2025","issue":"2","author":"Salenger","volume":"119","first-page":"280","unstructured":null,"article-title":"Cardiac surgical bleeding, transfusion, and quality metrics: joint consensus statement by the enhanced recovery after surgery cardiac society and society for the advancement of patient blood management.","journal-title":"Ann Thorac Surg","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjgh-2020-002716","key":"soi250084r55","year":"2020","issue":"9","author":"Williams","volume":"5","first-page":null,"unstructured":null,"article-title":"Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach.","journal-title":"BMJ Glob Health","doi-asserted-by":"publisher"},{"DOI":null,"key":"soi250084r14","year":"2014","issue":null,"author":"Wohlin","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"soi250084r9","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"General surgery: global trends & opportunities. Life Science Intelligence. Accessed May 2, 2025. https://www.lifesciencemarketresearch.com/market-reports/general-surgery-global-trends-opportunities-2018","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"soi250084r11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Higgins? JPT, Thomas? J, Chandler? J, . Cochrane Handbook for Systematic Reviews of Interventions, version 6.4. Updated August 22, 2024. Accessed April 5, 2025. http://www.training.cochrane.org/handbook","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"soi250084r13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Delgado L, Pompeu B, Martins G, Peñaranda L. Safety and efficacy of tranexamic acid in general surgery: a systematic review and meta-analysis of randomized controlled trials. PROSPERO 2025 CRD420251038412. April 23, 2025. Accessed November 11, 2025. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251038412","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"soi250084r28","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Prospective randomized phase IV open label comparative study of tranexamic acid plus standard of care vs standard of care for the reduction of blood loss in patients undergoing major abdominal surgery. ClinicalTrials.gov identifier: NCT00827931. Updated April 26, 2012. Accessed April 20, 2025. http://clinicaltrials.gov/show/nct00827931","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Surgery"],"reference-count":55,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,17]]},"references-count":55,"short-container-title":["JAMA Surg"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamasurg.2025.5498","is_oa":true,"title":"Perioperative Use of Tranexamic Acid in General Surgery","updated":"2025-12-21T03:41:08+00:00","published_date":"2025-12-17","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12712826/","pmh_id":"oai:pubmedcentral.nih.gov:12712826","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12712826/"}}},"created_at":"2026-01-08T08:12:02.165Z","updated_at":"2026-01-18T22:40:12.285Z","tags":[{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"condition","value":"Perioperative Bleeding","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"generic","value":"tranexamic acid","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"modality","value":"Antifibrinolytic","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"sample_size","value":"n=6976","value_numeric":6976},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"warning","value":"Absolute event rates and dosing regimens were not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"warning","value":"High heterogeneity for some outcomes may limit precision and generalizability.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.5498","tag_type":"warning","value":"Subgroup definitions (e.g., abdominal vs hepatobiliary) and perioperative timing are not detailed here.","value_numeric":null}],"summaries":{"what_studied":"A systematic review and meta-analysis of 26 randomized trials (n=6976) comparing prophylactic tranexamic acid with placebo in adults undergoing general surgery, searched through April 3, 2025, assessing blood loss, transfusion, major bleeding, venous thromboembolism, mortality, and length of stay.","key_result":"TXA reduced intraoperative blood loss (MD −35.85 mL; 95% CI −57.20 to −14.51; I2=91%), transfusion (RR 0.75; 95% CI 0.60-0.94; I2=54%), and major bleeding (RR 0.72; 95% CI 0.59-0.89; I2=0%), with no significant differences in venous thromboembolism (RR 1.09; 95% CI 0.62-1.92), mortality (RR 1.08; 95% CI 0.72-1.61), or length of stay (MD −0.54 days; 95% CI −1.15 to 0.06; I2=73%). Benefits for blood loss and transfusion were not seen in abdominal-only procedures; in hepatobiliary surgery, major bleeding decreased (RR 0.59; 95% CI 0.39-0.90; I2=0%).","limitations":"Heterogeneity was high for blood loss (I2=91%) and length of stay (I2=73%); effects varied by procedure, with abdominal-only procedures showing no benefit for blood loss or transfusion; safety estimates were imprecise, with wide CIs for venous thromboembolism and mortality.","practice_takeaway":"For adults undergoing general surgery, prophylactic TXA modestly reduces bleeding and transfusion without a detected rise in VTE or death; consider procedure-specific effects—benefits were clearer in hepatobiliary surgery and not observed for abdominal-only procedures."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Perioperative Bleeding"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Perioperative Bleeding"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Perioperative Bleeding"}}}]]

Papers